Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR

Victor H. Villar; Tra Ly Nguyen; Silvia Terés; Clément Bodineau; Raúl V. Durán

doi:10.1080/23723556.2017.1297284

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR

Victor H. Villar
, Tra Ly Nguyen
, Silvia Terés
, Clément Bodineau
, Raúl V. Durán^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

A master promoter of cell growth, mammalian target of rapamycin (mTOR) is upregulated in a large percentage of cancer cells. Still, targeting mTOR using rapamycin has a limited outcome in patients. Our recent results highlight the additional role of mTOR as a tumor suppressor, explaining these modest results in the clinic.

Original language	English
Article number	e1297284
Journal	Molecular and Cellular Oncology
Volume	4
Issue number	3
DOIs	https://doi.org/10.1080/23723556.2017.1297284
Publication status	Published - 4 May 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

autophagy
cancer metabolism
glutamoptosis
mTORC1
rapamycin
α-ketoglutarate

Access to Document

10.1080/23723556.2017.1297284

Handle.net

Persistent link

Cite this

@article{213efbfd565549549dd57f8fc377050a,

title = "Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR",

abstract = "A master promoter of cell growth, mammalian target of rapamycin (mTOR) is upregulated in a large percentage of cancer cells. Still, targeting mTOR using rapamycin has a limited outcome in patients. Our recent results highlight the additional role of mTOR as a tumor suppressor, explaining these modest results in the clinic.",

keywords = "autophagy, cancer metabolism, glutamoptosis, mTORC1, rapamycin, α-ketoglutarate",

author = "Villar, \{Victor H.\} and Nguyen, \{Tra Ly\} and Silvia Ter{\'e}s and Cl{\'e}ment Bodineau and Dur{\'a}n, \{Ra{\'u}l V.\}",

note = "Funding Information: This work was supported by funds from the following institutions: Institut National de la Sant{\'e}et de la Recherche M{\'e}dicale - INSERM, Fondation pour la Recherche M{\'e}dicale, Conseil R{\'e}gional d{\textquoteright}Aquitaine, Fondation ARC pour la Recherche sur le Cancer, SIRIC-BRIO, and Institut Europ{\'e}en de Chimie et Biologie. Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2017 The Author(s). Published with license by Taylor \& Francis Group, LLC. {\textcopyright} 2017, {\textcopyright} Victor H. Villar, Tra Ly Nguyen, Silvia Ter{\'e}s, Cl{\'e}ment Bodineau, and Ra{\'u}l V. Dur{\'a}n.",

year = "2017",

month = may,

day = "4",

doi = "10.1080/23723556.2017.1297284",

language = "English",

volume = "4",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis",

number = "3",

}

TY - JOUR

T1 - Escaping mTOR inhibition for cancer therapy

T2 - Tumor suppressor functions of mTOR

AU - Villar, Victor H.

AU - Nguyen, Tra Ly

AU - Terés, Silvia

AU - Bodineau, Clément

AU - Durán, Raúl V.

N1 - Funding Information: This work was supported by funds from the following institutions: Institut National de la Santéet de la Recherche Médicale - INSERM, Fondation pour la Recherche Médicale, Conseil Régional d’Aquitaine, Fondation ARC pour la Recherche sur le Cancer, SIRIC-BRIO, and Institut Européen de Chimie et Biologie. Publisher Copyright: © 2017, © 2017 The Author(s). Published with license by Taylor & Francis Group, LLC. © 2017, © Victor H. Villar, Tra Ly Nguyen, Silvia Terés, Clément Bodineau, and Raúl V. Durán.

PY - 2017/5/4

Y1 - 2017/5/4

N2 - A master promoter of cell growth, mammalian target of rapamycin (mTOR) is upregulated in a large percentage of cancer cells. Still, targeting mTOR using rapamycin has a limited outcome in patients. Our recent results highlight the additional role of mTOR as a tumor suppressor, explaining these modest results in the clinic.

AB - A master promoter of cell growth, mammalian target of rapamycin (mTOR) is upregulated in a large percentage of cancer cells. Still, targeting mTOR using rapamycin has a limited outcome in patients. Our recent results highlight the additional role of mTOR as a tumor suppressor, explaining these modest results in the clinic.

KW - autophagy

KW - cancer metabolism

KW - glutamoptosis

KW - mTORC1

KW - rapamycin

KW - α-ketoglutarate

UR - https://www.scopus.com/pages/publications/85050732576

U2 - 10.1080/23723556.2017.1297284

DO - 10.1080/23723556.2017.1297284

M3 - Article

AN - SCOPUS:85050732576

SN - 2372-3556

VL - 4

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 3

M1 - e1297284

ER -

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR

Abstract

UN SDGs

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this